Press releases
  • New York
  • Sept 7, 2021

Dr. John Stagg, a world-leader in the adenosine pathway, joins Scientific Advisory Board of Tarus Therapeutics, Inc.

  • NEW YORK
  • May 27, 2021

Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients

  • NEW YORK
  • Apr 28, 2021

Tarus Therapeutics seeks to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients

  • New York
  • Apr 6, 2021

Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients

  • New York
  • Mar 10, 2021

Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients

  • NEW YORK
  • Dec 2, 2020

Paolo Pucci, Tarus Board Appointment PR Dec 2020

  • NEW YORK
  • Nov 24, 2020

Tarus Therapeutics Expands R&D Team with Appointment of Brian Schwartz, M.D. as Interim Chief Medical Officer and Head of the Scientific Advisory Board

  • NEW YORK
  • Nov 19, 2020

Tarus Therapeutics Strengthens Its Board of Directors with Appointments of Mark Cohen and Robert Glassman

  • NEW YORK
  • May 20, 2020

Tarus Therapeutics Strengthens Board of Directors with the Appointment of Preeminent Life Sciences Industry Leaders

Tarus Therapeutics Inc., an innovative biotechnology company, announced the appointments of David R. Epstein and C. David Nicholson, PhD, to its Board of Directors, effective May 14, 2020

  • by Accesswire
  • Dec 23, 2019

A licensing deal with Impetis Biosciences, Ltd.

Tarus Therapeutics, Inc., (Tarus) and Impetis Biosciences, Ltd., (Impetis), announced today that Tarus has taken an IP license from Impetis to develop a portfolio of adenosine receptor antagonists for cancer immunotherapy as well as non-cancer indications.